Total Payments
$1.5M
2024 Payments
$121,903
Companies
43
Transactions
2,735
Medicare Patients
2,588
Medicare Billing
$385,882
Payment Breakdown by Category
Other$1.3M (87.8%)
Consulting$67,533 (4.5%)
Food & Beverage$57,028 (3.8%)
Travel$56,874 (3.8%)
Education$519.64 (0.0%)
Research$125.00 (0.0%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 799 | 87.5% |
| Consulting Fee | $67,533 | 26 | 4.5% |
| Food and Beverage | $57,028 | 1,386 | 3.8% |
| Travel and Lodging | $56,874 | 501 | 3.8% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,000 | 1 | 0.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,915 | 1 | 0.1% |
| Education | $519.64 | 19 | 0.0% |
| Unspecified | $125.00 | 1 | 0.0% |
| Gift | $59.40 | 1 | 0.0% |
Payments by Type
General
$1.5M
2,734 transactions
Research
$125.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $770,509 | 1,230 | $0 (2024) |
| Novo Nordisk Inc | $340,619 | 548 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $182,440 | 272 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $96,781 | 167 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $45,930 | 96 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $19,836 | 46 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $9,907 | 37 | $0 (2024) |
| CeQur Corporation | $8,873 | 6 | $0 (2024) |
| Insulet Corporation | $4,196 | 19 | $0 (2023) |
| Dexcom, Inc. | $4,075 | 71 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $121,903 | 227 | Lilly USA, LLC ($68,941) |
| 2023 | $140,210 | 254 | Lilly USA, LLC ($83,255) |
| 2022 | $174,197 | 299 | Lilly USA, LLC ($95,795) |
| 2021 | $193,121 | 288 | Lilly USA, LLC ($106,706) |
| 2020 | $149,766 | 254 | Lilly USA, LLC ($105,185) |
| 2019 | $237,262 | 569 | Lilly USA, LLC ($129,386) |
| 2018 | $196,944 | 395 | Lilly USA, LLC ($89,714) |
| 2017 | $278,150 | 449 | Lilly USA, LLC ($91,528) |
All Payment Transactions
2,735 individual payment records from CMS Open Payments — Page 1 of 110
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Diabetes | ||||||
| 12/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: Cardiology | ||||||
| 12/10/2024 | Alvogen Inc | TERIPARATIDE (Drug) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: OSTEOPOROSIS | ||||||
| 12/03/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 12/02/2024 | Intra-Sana Laboratories | RELTONE 200 MG (Drug), RELTONE 400 MG, GLYCATE | Food and Beverage | In-kind items and services | $86.61 | General |
| Category: GALLSTONES | ||||||
| 11/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Diabetes | ||||||
| 11/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Diabetes | ||||||
| 11/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Travel and Lodging | Cash or cash equivalent | $25.46 | General |
| Category: Diabetes | ||||||
| 11/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: Diabetes | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.61 | General |
| Category: DIABETES | ||||||
| 11/21/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Diabetes | ||||||
| 11/20/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $33.79 | General |
| 11/20/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.81 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | Cash or cash equivalent | $121.63 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $30.34 | General |
| Category: DIABETES | ||||||
| 11/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,025.00 | General |
| Category: DIABETES | ||||||
| 11/06/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: Diabetes | ||||||
| 10/30/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| 10/29/2024 | Intra-Sana Laboratories | RELTONE 200 MG (Drug), GLYCATE, RELTONE 400 MG | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: GALLSTONES | ||||||
| 10/23/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| 10/21/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $12.26 | General |
| Category: Obesity | ||||||
| 10/17/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Diabetes | ||||||
| 10/09/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| 10/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $119.66 | General |
| Category: DIABETES | ||||||
| 10/08/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,915.00 | General |
| Category: Endocrinology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 780 | 3,600 | $459,378 | $137,071 |
| 2022 | 8 | 652 | 2,384 | $355,568 | $107,943 |
| 2021 | 7 | 637 | 1,086 | $252,857 | $84,449 |
| 2020 | 8 | 519 | 834 | $160,131 | $56,420 |
Total Patients
2,588
Total Services
7,904
Medicare Billing
$385,882
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 369 | 712 | $214,312 | $68,670 | 32.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 24 | 2,400 | $158,400 | $44,293 | 28.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 85 | 85 | $39,185 | $10,474 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 54 | $21,762 | $7,429 | 34.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 52 | 84 | $10,584 | $2,386 | 22.5% |
| 83037 | Hemoglobin a1c level, by device for home use | Office | 2023 | 120 | 151 | $5,587 | $1,438 | 25.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 16 | 17 | $4,080 | $1,331 | 32.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 46 | 68 | $5,236 | $822.86 | 15.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 25 | 29 | $232.00 | $227.36 | 98.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 311 | 586 | $176,386 | $57,578 | 32.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 17 | 1,380 | $91,080 | $23,834 | 26.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 99 | 99 | $45,639 | $12,739 | 27.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 47 | 65 | $26,195 | $10,140 | 38.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 37 | 63 | $7,938 | $1,792 | 22.6% |
| 83037 | Hemoglobin a1c level, by device for home use | Office | 2022 | 98 | 137 | $5,069 | $1,314 | 25.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 30 | 41 | $3,157 | $506.87 | 16.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 13 | 13 | $104.00 | $38.52 | 37.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 259 | 576 | $169,423 | $59,461 | 35.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 109 | 109 | $49,171 | $14,265 | 29.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 33 | 44 | $17,332 | $6,630 | 38.3% |
| 83037 | Hemoglobin a1c level, by device for home use | Office | 2021 | 112 | 189 | $6,798 | $1,825 | 26.9% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 25 | 48 | $5,760 | $1,444 | 25.1% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 37 | 51 | $3,839 | $616.32 | 16.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 62 | 69 | $534.00 | $207.00 | 38.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 210 | 467 | $113,014 | $39,835 | 35.2% |
About Dr. Daniel Nadeau, MD
Dr. Daniel Nadeau, MD is a Internal Medicine healthcare provider based in Newport Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215902226.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Nadeau, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $121,903 received in 2024. These payments were reported across 2,735 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M).
As a Medicare-enrolled provider, Nadeau has provided services to 2,588 Medicare beneficiaries, totaling 7,904 services with total Medicare billing of $385,882. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Newport Beach, CA
- Active Since 02/22/2006
- Last Updated 04/20/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1215902226
Products in Payments
- TRULICITY (Drug) $411,923
- JARDIANCE (Drug) $387,487
- MOUNJARO (Drug) $128,323
- FARXIGA (Drug) $90,277
- Ozempic (Drug) $83,983
- Rybelsus (Drug) $70,297
- RYBELSUS (Drug) $60,990
- INVOKANA (Drug) $45,924
- Tresiba (Drug) $31,229
- Victoza (Drug) $15,104
- SOLIQUA (Drug) $14,586
- CeQur Simplicity (Device) $8,873
- Xultophy 100/3.6 (Drug) $7,990
- BYDUREON (Drug) $5,782
- TOUJEO (Drug) $4,866
- Omnipod (Device) $4,196
- DEXCOM G7 GSS (161) (Medical Supply) $1,915
- AFREZZA (Drug) $1,679
- Kerendia (Drug) $1,067
- Dexcom G6 Transmitter (Medical Supply) $952.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Newport Beach
Dr. Ehab Mady, D.o, D.O
Internal Medicine — Payments: $256,298
Internal Medicine $256,298
Ryan Klein, Md, MD
Internal Medicine — Payments: $159,192
Internal Medicine $159,192
Wael Harb, Md, MD
Internal Medicine — Payments: $130,572
Internal Medicine $130,572
Laura Salazar, Md, MD
Internal Medicine — Payments: $129,472
Internal Medicine $129,472
David Brouwer, Md, MD
Internal Medicine — Payments: $71,027
Internal Medicine $71,027
Dr. Gregory Robertson, M.d, M.D
Internal Medicine — Payments: $35,951
Internal Medicine $35,951